Allarity Therapeutics, Inc. Gain (Loss) on Sale of Derivatives
Allarity Therapeutics, Inc. (ALLR) reported Gain (Loss) on Sale of Derivatives of $1.00 million for the 9-month period ending 2021-09-30, per its 10-Q/A filed 2022-05-17.
Discontinued › Income Statement › Other Income
us-gaap:GainLossOnSaleOfDerivatives · last filed 2022-05-17
- 2021-09-30: Gain (Loss) on Sale of Derivatives 9 month $1.00M.
| Period end | Gain (Loss) on Sale of Derivatives 9 month |
|---|---|
| 2021-09-30 | $1.00M 10-Q/A · filed 2022-05-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PALATIN TECHNOLOGIES INC (PTN) | United States | $0.017B | -5.36 |
| Lipocine Inc. (LPCN) | United States | $0.017B | -1.79 |
| Pasithea Therapeutics Corp. (KTTA) | United States | $0.017B | -0.81 |
| Biofrontera Inc. (BFRI) | United States | $0.018B | -2.13 |
| Korsana Biosciences, Inc. (CYCN) | United States | $0.016B | |
| Citius Pharmaceuticals, Inc. (CTXR) | United States | $0.016B | -133.06 |
| Rocket One Inc. (RKTO) | United States | $0.019B | |
| Lantern Pharma Inc. (LTRN) | United States | $0.015B | -2.87 |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH) | United States | $0.019B | -0.31 |
| Anebulo Pharmaceuticals, Inc. (ANEB) | United States | $0.015B |